Search
AOD9604
go.drugbank.com/drugs/DB06388ExperimentalAOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.
Betamethasone phosphate
go.drugbank.com/drugs/DB14669ApprovedVet approvedBetamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible betamethasone to agonize glucocorticoid receptors. Betamethasone provides greater anti-inflammatory activity than prednisolone with less sodium...
Dihydrotachysterol
go.drugbank.com/drugs/DB01070ApprovedWithdrawnA vitamin D that can be regarded as a reduction product of vitamin D2.
BL-1020
go.drugbank.com/drugs/DB05687InvestigationalBL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
Verubulin
go.drugbank.com/drugs/DB05585InvestigationalAntineoplastic; a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
LIC-477
go.drugbank.com/drugs/DB05363ExperimentalLIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.
ALKS 29
go.drugbank.com/drugs/DB05723ExperimentalALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.
Tofisopam
go.drugbank.com/drugs/DB08811InvestigationalAlthough Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe. … The D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome.
Zanapezil
go.drugbank.com/drugs/DB04859ExperimentalZanapezil (TAK-147) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment.
Cyclo(prolylglycyl)
go.drugbank.com/drugs/DB04541Investigationalwith Atazanavir and Dexamethasone for COVID-19). … NA-831 (Traneurocin), is under investigation in two clinical trials: NCT03538522 (completed, for mild cognitive impairment and Alzheimer’s disease) and NCT04452565 (unknown status, combination therapy